News About: Pharm. Industry
Hanmi, MSD to cooperate over Amosartan
Hanmi Pharmaceutical and the US based Merck & Co. signed their second contract to sell Hanmi's incrementally modified hypertensive amlodipine product Amosartan in 30 countries, under Merck's brand Cozzar XQ.
The co...
Drug makers’ profitability worsen on aggressive promotion
Domestic pharmaceutical firms, which have increased their revenues during the last few years, are seeing profitability worsen on aggressive promotion.
Yakup com. said most of Korean drug manufacturers are seeing th...
Daewoong’s monthly per capita sales top 42.4 million won per
The per capita sales in Daewoong Pharmaceutical stood at 42.4 million won per month, according to Yakup. com, pharmaceutical information provider.
Yakup. com. said that the average monthly revenue of 49 pharmaceuti...
Dong-A opens global standard R&D center
Dong-A Pharmaceutical Chairman Kang Shin-ho called on his company to develop its own medicines incessantly, Tuesday.
The move comes at a time when Dong-A has been facing a further drop in sales amidst a fiercer com...
Hanmi Holdings wins US patent on immunoglobin
Hanmi Holdings said Monday it has obtained the U.S. patent entitled “A method for the mass production of immunoglobulin Fc region deleted initial methionine residues” using LAPSCOVERY Technology (Long Acting Protein/P...
Roche Korea to discontinue importation of Tiberal tablets
Roche Korea says customers will not be able to import Tiberal tablets in the future based on its headquarters’ abrupt notice.
“We will be in no position to import the product, even though the remaining stocks are t...
Pharmaceutical firms suffer poor Q1 results
A total of KOSPI-listed 33 Korean pharmaceutical companies saw their first-quarter revenues worsen sharply, buffeted by dramatic changes in the business environment such as regulations by the government, conflicts amo...
36 pharmaceutical firms’ debt ratio hovers at 57% on average
The debt ratio of the KOSPI-listed 36 pharmaceutical firms in the country averaged 57 percent as of the end of last year, down 2 percentage points from 2009, according to Yakup.com, a pharmaceutical information provid...
Dong-A develops third drug
The Korea Food and Drug Administration has recently approved Dong-A Pharmaceutical’s anti-ulcerant drug Motilitone derived from natural substance.
Motilitone is Dong-A’s third homegrown medicine following Stillen a...
Wholesaler margin is under discussion with Takeda, KPWA says
The Korea Pharmaceutical Wholesaler Association says it is now under discussion with Takeda Korea over thorny issues, such as wholesaler margin and increase of associate wholesalers.
In a press interview, the KPWA ...
